The Research Institute of Chemical Diversity, one of the R&D arms of Russia’s KhimRar Hi-Tech Center, has inked a joint research and project development agreement with Belgium’s Janssen Pharmaceutica NV and Tibotec Pharmaceuticals, Rusnanonet Russian National Nanotech Network reports.
With its expertise and technology to do integrated research for new drugs, the Institute, under terms of the agreement, will reportedly focus on new ‘small molecules’ to be discovered for biotargets that the three partners jointly select. Janssen and Tibotec are compelled by the agreement to partially cover the Institute’s costs of research on each of their joint projects. The Russian partner will also be eligible for some ‘success’ payments.
Under plan, most research will be conducted at the Institute’s Moscow-based facilities.
According to Institute chairman Nikolai Savchuk, his company “aims to look for brand new forms of innovative R&D-related cooperation” and has plans to increase its presence in emerging markets.
The Research Institute of Chemical Diversity, headquartered on KhimRar Hi-Tech Center premises, is a sizable Russian private R&D hub offering innovation drug makers contract-based preclinical and clinical trials services as well as lab and industrial testing regulations development for synthetic and bio-engineered drugs developed by both Russian and international pharmas.
Belgium’s Janssen Pharmaceutica is part of international Janssen Pharmaceutical Group and a member of the Johnson & Johnson family of companies. It focuses on pathology areas in neuroscience, oncology and infectious diseases, and develops new vaccines.
Tibotec Pharmaceuticals is the Irish subsidiary of Tibotec-Virco Comm. VA, a pharmaceutical R&D company based in Mechelen, Belgium. It is one of European R&D majors at the forefront of HIV and other infectious disease discovery research.